{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"IRD","limit":50},"count":50,"signals":[{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":54,"context":"ertain investors 3,138,338 shares of its Common Stock for gross proceeds of approximately $3.5million. The August2025 Private Placement was led by Cam Gallagher, Chair of the Companys Board, with an investment of $1.0million, along with participation by Sean Ainsworth, the lead independent director of the Board, in the amount of $0.1million, and other investors for the balance of the Private Placement. Agreements with t","filed_date":"2026-03-23","accession":"0001140361-26-010757","full_text":"https://origin.rootz.global/static/filing/0001140361-26-010757.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"adverse results that may not satisfy U.S. Food and Drug Administration (FDA) requirements to further develop our therapeutic products. | | | | | Delays or difficulties associated with patient enrollment in clinical trials may affect our ability to conduct and complete those clinical trials and obtain necessary regulatory approvals. | | | | | Changes in regulatory requirements could result in","filed_date":"2026-03-12","accession":"0001140361-26-009247","full_text":"https://origin.rootz.global/static/filing/0001140361-26-009247.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":46,"context":"reased litigation and judicial scrutiny. Any resulting changes in regulation may result in unexpected delays, increased costs, or other negative impacts that are difficult to predict but could have a material adverse effect on our business and financial condition. For example, certain of these changes could impose additional limitations on the rates we will be able to charge for our future products or the amounts of rei","filed_date":"2026-03-12","accession":"0001140361-26-009247","full_text":"https://origin.rootz.global/static/filing/0001140361-26-009247.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":17,"context":"al Property Rights has the meaning set forth in Section 3.11 hereof. Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall mean any change, event, circumstance, development, condition, occurrence or effect that, individually or in the aggregate, has had, or would reasonably be expected to have, a material adverse e","filed_date":"2026-02-19","accession":"0001140361-26-006176","full_text":"https://origin.rootz.global/static/filing/0001140361-26-006176.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":22,"context":"ights shall have the meaning ascribed to such term inSection 3.1(p). Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall mean any change, event, circumstance, development, condition, occurrence or effect that, individually or in the aggregate, (a) is materially adverse to the business, financial condition, proper","filed_date":"2025-11-06","accession":"0001140361-25-040796","full_text":"https://origin.rootz.global/static/filing/0001140361-25-040796.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":18,"context":"failure, or provide inconclusive or adverse results that may not satisfy FDA requirements to further develop our therapeutic products. | | | | | Delays or difficulties associated with patient enrollment in clinical trials may affect our ability to conduct and complete those clinical trials and obtain necessary regulatory approvals. | | | | | Changes in regulatory requirements could result in","filed_date":"2025-03-31","accession":"0001140361-25-011410","full_text":"https://origin.rootz.global/static/filing/0001140361-25-011410.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":52,"context":"summary in their entirety for additional information. Risks Related to the Opus Acquisition | | | Failure to successfully integrate our businesses with Former Opus (as defined below) could have a material adverse effect on our business, financial condition and results of operations. | | | | | The Opus Acquisition (as defined below) significantly expanded our product pipeline and business operations and shifted o","filed_date":"2025-03-31","accession":"0001140361-25-011410","full_text":"https://origin.rootz.global/static/filing/0001140361-25-011410.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":20,"context":"t or other restriction. Lock-Up Agreements means the lock-up agreements that are delivered on the date hereof by each of the Companys officers and directors, in the form of Exhibit A attached hereto. Material Adverse Effect means (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business, prospects o","filed_date":"2025-03-24","accession":"0001140361-25-010064","full_text":"https://origin.rootz.global/static/filing/0001140361-25-010064.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":36,"context":"ing of property requires such qualification, except to the extent that the failure to be so qualified or in good standing would not reasonably be expected, individually or in the aggregate, to have a material adverse effect on the condition (financial or otherwise), earnings, results of operations, business, properties, operations, assets, liabilities or prospects of the Company and its Subsidiaries, taken as a whole, w","filed_date":"2025-01-14","accession":"0001140361-25-001013","full_text":"https://origin.rootz.global/static/filing/0001140361-25-001013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"sion under mesopic (low) light conditions following keratorefractive surgery, we received FDA agreement under Special Protocol Assessment (SPA) for LYNX-2, a Phase 3 Trial of PS. LYNX-2 continues enrollment. LYNX-3, an additional Phase 3 study for decreased vision under mesopic (low) light conditions following keratorefractive surgery, has commenced. Basis of Presentation The accompanying condensed f","filed_date":"2024-11-12","accession":"0001140361-24-046045","full_text":"https://origin.rootz.global/static/filing/0001140361-24-046045.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":23,"context":"n this Quarterly Report on Form 10-Q. Risks Related to the Opus Acquisition The integration with Former Opus presents challenges, and the failure to successfully integrate the businesses could have a material adverse effect on our business, financial condition and results of operations. The Opus Acquisition combined two independent companies with different operations and focuses on drug development. We are devoting sign","filed_date":"2024-11-12","accession":"0001140361-24-046045","full_text":"https://origin.rootz.global/static/filing/0001140361-24-046045.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":49,"context":"ny’s independent public accounting firm for the fiscal year ending December 31, 2024; | | | | ​ | ​ | Approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the accompanying Proxy Statement; | | | | ​ | ​ | Approve, pursuant to the Nasdaq Listing Rules, the potential issuance of shares of common stock to Lincoln Park Capita","filed_date":"2024-04-29","accession":"0001140361-24-023004","full_text":"https://origin.rootz.global/static/filing/0001140361-24-023004.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":42,"context":"-ophthalmic indications. | | Viatris has exclusive global rights to commercialize RYZUMVI and PS in key global markets. Viatris failure to timely develop or commercialize these products would have a material adverse effect on our business and operating results. We granted Viatris an exclusive right to commercialize RYZUMVI and PS in key global markets. Additionally, we granted Viatris the exclusive right and license to","filed_date":"2024-03-08","accession":"0001140361-24-012399","full_text":"https://origin.rootz.global/static/filing/0001140361-24-012399.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":23,"context":"ppointment our independent registered public accounting firm for the fiscal year ending December31, 2023, and (3) to approve (on an advisory basis) whether an advisory vote on the compensation of our named executive officers should occur once every one, two or three years. The Board of Directors unanimously recommends that you vote FOR the election of each of the director nominees, and FOR the ratification of the appoin","filed_date":"2023-05-01","accession":"0001140361-23-022044","full_text":"https://origin.rootz.global/static/filing/0001140361-23-022044.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":18,"context":"indication. | | | | | Viatris has exclusive global rights to commercialize our Nyxol products in key global markets. Viatris failure to timely develop or commercialize these products would have a material adverse effect on our business and operating results. | | | | | The results of previous clinical trials may not be predictive of future results, and the results of our current and planned clinical trials may no","filed_date":"2023-03-30","accession":"0001140361-23-014868","full_text":"https://origin.rootz.global/static/filing/0001140361-23-014868.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":15,"context":"esent Board, or the Board will have a vacancy, which it may fill at a later date or reduce the size of the Board. We have no reason to believe that any nominee will be unwilling or unable to serve if elected as a director. Additional information regarding the director nominees is set forth below. Mina Sooch Mina Sooch, MBA, has served as Ocuphires Chief Executive Officer, President, Treasurer, and as a member of the B","filed_date":"2022-04-27","accession":"0001140361-22-016115","full_text":"https://origin.rootz.global/static/filing/0001140361-22-016115.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":26,"context":"monstrated promising clinical data for use in the multiple ophthalmic indications mentioned above. Ocuphire reported positive top-line data from the first Phase 3 trial (MIRA-2) for RM, completed enrollment in a 2nd Phase 3 RM trial (MIRA-3) in February 2022, and completed enrollment on a pediatric safety study (MIRA-4) for RM in March 2022. Ocuphire also reported positive top-line data from a Phase","filed_date":"2022-03-24","accession":"0001140361-22-011015","full_text":"https://origin.rootz.global/static/filing/0001140361-22-011015.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":16,"context":"not gain approval or achieve market acceptance of that candidate, and its business and financial results will be harmed. Changes in tax laws or regulations that are applied adversely to us may have a material adverse effect on our business, cash flow, financial condition or results of operations. New tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our busin","filed_date":"2022-03-24","accession":"0001140361-22-011015","full_text":"https://origin.rootz.global/static/filing/0001140361-22-011015.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":13,"context":"of Contents](#TABLEOFCONTENTS) Corporate History On November 5, 2020, Ocuphire (formerly known as Rexahn Pharmaceuticals, Inc., and prior to the merger, referred to as Rexahn), completed its reverse merger with Ocuphire Pharma, Inc. (Private Ocuphire), in accordance with the terms of the Agreement and Plan of Merger, dated as of June 17, 2020, as amended, by and among Rexahn, Private Ocuphire, and Razor Mer","filed_date":"2022-03-24","accession":"0001140361-22-011015","full_text":"https://origin.rootz.global/static/filing/0001140361-22-011015.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":29,"context":"the Proxy Statement, each to serve a one-year term, (2) to ratify the appointment our independent registered public accounting firm for the fiscal year ending December31, 2021 and (3) to approve our named executive officers compensation in an advisory vote. The Board of Directors unanimously recommends that you vote FOR the election of each of the director nominees, FOR the ratification of the appointment of our indepe","filed_date":"2021-04-26","accession":"0001140361-21-014256","full_text":"https://origin.rootz.global/static/filing/0001140361-21-014256.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":39,"context":"d in the Registration Statement and the Prospectus, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, have a material adverse effect or would reasonably be expected to have a material adverse effect on or affecting the assets, business, operations, earnings, properties, condition (financial or otherwise), prospects, stockholders e","filed_date":"2021-03-11","accession":"0001140361-21-008130","full_text":"https://origin.rootz.global/static/filing/0001140361-21-008130.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":14,"context":"cient interest in the market will exist for the products and services being produced by, or for, it. Any lack of sufficient demand for the products contemplated to be provided by Ocuphire will have a material adverse effect on it. If the FDA or a comparable foreign regulatory authority approves generic versions of Ocuphires product candidates that receive marketing approval, or if such authorities do not grant Ocuphires","filed_date":"2021-03-11","accession":"0001140361-21-008099","full_text":"https://origin.rootz.global/static/filing/0001140361-21-008099.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":13,"context":"cal year ended December 31, 2020. EXPLANATORY NOTE On November5, 2020, Ocuphire (formerly known as Rexahn Pharmaceuticals, Inc., and prior to the merger, referred to as Rexahn), completed its reverse merger with Ocuphire Pharma, Inc. (Private Ocuphire), in accordance with the terms of the Agreement and Plan of Merger, dated as of June17, 2020, as amended, by and among Rexahn, Private Ocuphire, and Razor Merg","filed_date":"2021-03-11","accession":"0001140361-21-008099","full_text":"https://origin.rootz.global/static/filing/0001140361-21-008099.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":48,"context":"such Buyer, except in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or violations which would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of such Buyer to perform its obligations hereunder. 3. REPRESENTATIONS AND WARRANTIES OF OCUPHIRE. Ocuphire represents and warrants to each of the Buyers that, as of the Initial Subscr","filed_date":"2020-07-01","accession":"0001140361-20-015244","full_text":"https://origin.rootz.global/static/filing/0001140361-20-015244.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":17,"context":"ne 2015 from his position as a Vice President of PwC Strategy&, a global strategy consulting firm. PwC Strategy& was formerly Booz & Company and Booz Allen Hamilton, Inc. (Booz Allen). Prior to being elected Vice President at Booz Allen in 1993, he served as staff member and Engagement Manager at Booz Allen from 1984 to 1993. Prior to joining Booz Allen, Mr. Beever served in various management roles at McGraw-Edison Co","filed_date":"2020-04-29","accession":"0001140361-20-010048","full_text":"https://origin.rootz.global/static/filing/0001140361-20-010048.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"genes ABRAXANE (paclitaxel protein-bound particles for injectable suspension) as a first-line treatment in patients newly diagnosed with metastatic pancreatic cancer. The trial reached its target enrollment in February 2019. As of July 24, 2019, an overall response rate of 23% had been observed in 40 patients that had at least one scan on treatment. Preliminary and unaudited data indicates that the m","filed_date":"2020-02-21","accession":"0001140361-20-003785","full_text":"https://origin.rootz.global/static/filing/0001140361-20-003785.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":15,"context":"ses. We believe that we and the third parties that work with us are in compliance in all material respects with currently applicable rules and regulations, however, any failure to comply could have a material negative impact on our ability to successfully develop and commercialize our products, and therefore on our financial performance. In addition, the rules and regulations that apply to our business are subject to cha","filed_date":"2020-02-21","accession":"0001140361-20-003785","full_text":"https://origin.rootz.global/static/filing/0001140361-20-003785.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":24,"context":"uditors and to approve an adjournment of the Annual Meeting. | | | Q: | Who will count the votes? | | | A: | Votes at the Annual Meeting will be counted by an inspector of election, who will be appointed by the Board of Directors or the chairman of the Annual Meeting. | | | Q: | What is the effect of not voting? | | | A: | If you are a beneficial owner of shares in street name and do not provide the broker, bank or oth","filed_date":"2019-04-29","accession":"0001140361-19-007856","full_text":"https://origin.rootz.global/static/filing/0001140361-19-007856.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"ses. We believe that we and the third parties that work with us are in compliance in all material respects with currently applicable rules and regulations, however, any failure to comply could have a material negative impact on our ability to successfully develop and commercialize our products, and therefore on our financial performance. In addition, the rules and regulations that apply to our business are subject to cha","filed_date":"2019-03-07","accession":"0001140361-19-004539","full_text":"https://origin.rootz.global/static/filing/0001140361-19-004539.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":17,"context":"f the assets or properties owned, leased or licensed by it requires such qualification, except for such jurisdictions where the failure to so qualify individually or in the aggregate would not have a material adverse effect on the assets, properties, condition, financial or otherwise, or in the results of operations, business affairs or business prospects of the Company (a Material Adverse Effect); and to the Companys k","filed_date":"2019-01-25","accession":"0001140361-19-001600","full_text":"https://origin.rootz.global/static/filing/0001140361-19-001600.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":24,"context":"have the meaning ascribed to such term in Section 3.1(p). Lien means a material lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. 3 Material Adverse Effect shall have the meaning ascribed to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(n). Money Laundering Laws shall have the meaning ascribed","filed_date":"2018-10-19","accession":"0001140361-18-040906","full_text":"https://origin.rootz.global/static/filing/0001140361-18-040906.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":55,"context":"shares is required to approve the authorized share increase. | | | Q: | Who will count the votes? | | | A: | Votes at the Annual Meeting will be counted by an inspector of election, who will be appointed by the Board of Directors or the chairman of the Annual Meeting. | | | Q: | What is the effect of not voting? | | | A: | If you are a beneficial owner of shares in street name and do not provide the broker, bank or oth","filed_date":"2018-04-23","accession":"0001140361-18-019246","full_text":"https://origin.rootz.global/static/filing/0001140361-18-019246.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":7,"context":"ses. We believe that we and the third parties that work with us are in compliance in all material respects with currently applicable rules and regulations, however, any failure to comply could have a material negative impact on our ability to successfully develop and commercialize our products, and therefore on our financial performance. In addition, these rules and regulations are subject to change. For example, in Dece","filed_date":"2018-03-09","accession":"0001140361-18-012817","full_text":"https://origin.rootz.global/static/filing/0001140361-18-012817.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":24,"context":"ghts shall have the meaning ascribed to such term in Section 3.1(p). Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning ascribed to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(n). Money Laundering Laws shall have the meaning ascribed","filed_date":"2017-10-13","accession":"0001140361-17-038582","full_text":"https://origin.rootz.global/static/filing/0001140361-17-038582.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":24,"context":"ghts shall have the meaning ascribed to such term in Section 3.1(p). Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning ascribed to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(n). Money Laundering Laws shall have the meaning ascribed","filed_date":"2017-06-07","accession":"0001140361-17-024258","full_text":"https://origin.rootz.global/static/filing/0001140361-17-024258.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":59,"context":"for holding the non-binding vote on executive compensation. | | | Q: | Who will count the votes? | | | A: | Votes at the Annual Meeting will be counted by an inspector of election, who will be appointed by the Board of Directors or the chairman of the Annual Meeting. | | | Q: | What is the effect of not voting? | | | A: | If you are a beneficial owner of shares in street name and do not provide the broker, bank or oth","filed_date":"2017-02-24","accession":"0001140361-17-009142","full_text":"https://origin.rootz.global/static/filing/0001140361-17-009142.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":8,"context":"ses. We believe that we and the third parties that work with us are in compliance in all material respects with currently applicable rules and regulations, however, any failure to comply could have a material negative impact on our ability to successfully develop and commercialize our products, and therefore on our financial performance. In addition, these rules and regulations are subject to change. For example, in Dece","filed_date":"2017-02-24","accession":"0001140361-17-009132","full_text":"https://origin.rootz.global/static/filing/0001140361-17-009132.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":24,"context":"ghts shall have the meaning ascribed to such term in Section 3.1(p). Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning ascribed to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(n). 3 Money Laundering Laws shall have the meaning ascribe","filed_date":"2016-09-14","accession":"0001140361-16-079727","full_text":"https://origin.rootz.global/static/filing/0001140361-16-079727.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":52,"context":"amendment and restatement of the Companys stock option plan. | | | Q: | Who will count the votes? | | | A: | Votes at the Annual Meeting will be counted by an inspector of election, who will be appointed by the Board of Directors or the chairman of the Annual Meeting. | | | Q: | What is the effect of not voting? | | | A: | If you are a beneficial owner of shares in street name and do not provide the broker, bank or oth","filed_date":"2016-04-18","accession":"0001140361-16-061408","full_text":"https://origin.rootz.global/static/filing/0001140361-16-061408.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":25,"context":"ghts shall have the meaning ascribed to such term in Section 3.1(p). Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning ascribed to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(n). Money Laundering Laws shall have the meaning ascribed","filed_date":"2016-02-26","accession":"0001140361-16-055010","full_text":"https://origin.rootz.global/static/filing/0001140361-16-055010.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":25,"context":"ghts shall have the meaning ascribed to such term in Section 3.1(p). Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning ascribed to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(n). Money Laundering Laws shall have the meaning ascribed","filed_date":"2015-11-06","accession":"0001140361-15-039908","full_text":"https://origin.rootz.global/static/filing/0001140361-15-039908.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":22,"context":"rove the reverse stock split and authorized share reduction. | | | Q: | Who will count the votes? | | | A: | Votes at the Annual Meeting will be counted by an inspector of election, who will be appointed by the Board of Directors or the chairman of the Annual Meeting. | | | Q: | What is the effect of not voting? | | | A: | If you are a beneficial owner of shares in street name and do not provide the broker, bank or oth","filed_date":"2014-04-18","accession":"0001140361-14-017095","full_text":"https://origin.rootz.global/static/filing/0001140361-14-017095.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":20,"context":"y interest, encumbrance, right of first refusal, preemptive right or other restriction. LS means Lowenstein Sandler LLP, with offices located at 1251 Avenue of the Americas, New York, New York 10020. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(m). NYSE MKT Approval means the approval by the NYSE MKT o","filed_date":"2014-01-15","accession":"0001140361-14-002191","full_text":"https://origin.rootz.global/static/filing/0001140361-14-002191.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":20,"context":"ghts shall have the meaning ascribed to such term in Section 3.1(n). Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(m). NYSE MKT Approval means the approval by the NYSE MKT o","filed_date":"2013-10-16","accession":"0001140361-13-038816","full_text":"https://origin.rootz.global/static/filing/0001140361-13-038816.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":13,"context":"lation of the number of votes considered to be present at the Annual Meeting for purposes of determining a quorum. Votes at the Annual Meeting will be counted by an inspector of election, who will be appointed by the Board of Directors or the chairman of the Annual Meeting.If sufficient votes for approval of the matters to be considered at the Annual Meeting have not been received prior to the meeting date, the Company may postpon","filed_date":"2013-04-22","accession":"0001140361-13-017009","full_text":"https://origin.rootz.global/static/filing/0001140361-13-017009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":13,"context":"lation of the number of votes considered to be present at the Annual Meeting for purposes of determining a quorum. Votes at the Annual Meeting will be counted by an inspector of election, who will be appointed by the Board of Directors or the chairman of the Annual Meeting.If sufficient votes for approval of the matters to be considered at the Annual Meeting have not been received prior to the meeting date, the Company may postpon","filed_date":"2011-04-26","accession":"0001140361-11-023216","full_text":"https://origin.rootz.global/static/filing/0001140361-11-023216.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"ing exclusivity after approval and tax incentives for clinical research. Archexinis currently in Phase II clinical trials for the treatment of pancreatic cancer with several patients enrolled and enrollment continuing in 2011. ArchexinsPhase II clinical trial protocol for the treatment of renal cell carcinoma (RCC) was accepted by the FDA, but issues with enrollment have delayed the trial. Such enrol","filed_date":"2011-03-16","accession":"0001140361-11-017219","full_text":"https://origin.rootz.global/static/filing/0001140361-11-017219.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"ation of services. On May 24, 2010 and June 15, 2010, the Company issued 200,000 shares of common stock. During the quarter ended September 30, 2010, the Company issued shares of common stock in installments of 400,000 and 200,000 on August 2, 2010 and September 21, 2010. The total shares of common stock issued had a fair value of $1,663,999, based upon the market value of the Companys stock on their","filed_date":"2010-11-15","accession":"0001140361-10-045796","full_text":"https://origin.rootz.global/static/filing/0001140361-10-045796.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"x Months Ended June 30, 2010 and 2009 (Unaudited) For grants to non-employee consultants of the Company after September 12, 2005, the vesting period is between one to three years, subject to the fulfillment of certain conditions in the individual stock option grant agreements, or 100% upon the occurrence of certain events specified in the individual stock option grant agreements. Options authorized f","filed_date":"2010-08-16","accession":"0001140361-10-033716","full_text":"https://origin.rootz.global/static/filing/0001140361-10-033716.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRD","company":"Opus Genetics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"Agreement originally provided for $10,000 a month in cash payments and a stock option grant for 50,000 options, of which 25% vested on March 31, 2023, with the remainder vesting in equal monthly installments over 36 months. The 2022 Pepose Consulting Agreement was amended on September 19, 2022 to provide for vesting acceleration for stock-based awards in the event of a change in control, and on Decem","filed_date":"2025-05-15","accession":"0001140361-25-019266","full_text":"https://origin.rootz.global/static/filing/0001140361-25-019266.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"55d0791d2e1406815c27789b401cc32656f71666812f725ff9f658743b2e0113","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"dee541a897c7a071281401bca11eac73db4d325f5d8db8a5ade7e3738456ba5e","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256() || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":65,"hourly_limit":500,"remaining":435,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}